Kaplan–Meier survival analysis revealed no significant differences in overall survival between low- and high-expressing groups of BRAF among patients with breast cancer (median survival 155.37 vs. 153.87 months, p = 0.888, respectively, Figure 4(a)). This evidence concerns the gene BRAF and breast carcinoma.